Zai Lab

Company

Zai Lab’s Q2 2022 Financials Show Revenue Growth and R&D Cost Cut

Fineline Cube Aug 10, 2022

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q2 2022 financial report,...

Company Drug

Zai Lab Ltd Makes FcRn Antagonist Efgartigimod Available for Myasthenia Gravis Treatment

Fineline Cube Jun 15, 2022

Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced the availability of efgartigimod, the world’s...

Company Drug

Zai Lab’s Repotrectinib Earns Two Breakthrough Therapy Designations in China for ROS1+ NSCLC

Fineline Cube Jun 13, 2022

China-based biopharma Zai Lab Ltd (NASDAQ: ZLAB) announced receiving two breakthrough therapy designations (BTDs) from...

Company Drug

Zai Lab’s Optune Approved by China’s NMPA, Offering New Hope for Glioblastoma Patients

Fineline Cube May 14, 2020

Zai Lab Ltd (NASDAQ: ZLAB), a biopharmaceutical company based in China, has received approval from...

Company Drug

MSD’s Gardasil 9 Approved in China for Males Aged 16 to 26

Policy / Regulatory

NHC Urges Hospitals to Establish Healthy Weight Management Clinics by June

Company Deals

Mabwell and DP Technology Collaborate to Build Biopharma AI Platform for Drug Development

Company Drug

Bristol-Myers Squibb Wins FDA Approval for Opdivo-Yervoy Combo in First-Line HCC Treatment